WilmerHale Represents Akouos in Acquisition by Lilly

WilmerHale Represents Akouos in Acquisition by Lilly

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

On October 18, 2022, Eli Lilly and Company announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery and AAV gene therapy. The acquisition will enable the company to leverage Lilly's resources and global reach to further its mission of making healthy hearing available to all. Under the terms of the agreement, Lilly will commence a tender offer to acquire outstanding shares of Akouos for an aggregate purchase price of approximately $487 million.

The WilmerHale team representing Akouos was led by Rosemary G. Reilly, Joseph Conahan, Andrew Bonnes, Molly Fox, Will Myer, Erin Garrity and Chris Gravallese.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel